Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale
Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.